Published in Neurology on August 27, 2002
CSF hypocretin-1 levels in narcolepsy, Kleine-Levin syndrome, and other hypersomnias and neurological conditions. J Neurol Neurosurg Psychiatry (2003) 1.69
The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy threshold. BMC Neurosci (2013) 0.92
Diagnosis and treatment of sleep disorders: a brief review for clinicians. Dialogues Clin Neurosci (2003) 0.91
Hypothalamic orexin's role in exacerbated cutaneous vasodilation responses to an anxiogenic stimulus in a surgical menopause model. Psychoneuroendocrinology (2015) 0.78
Understanding how discrete populations of hypothalamic neurons orchestrate complicated behavioral states. Front Syst Neurosci (2015) 0.77
Heart rate changes accompanying periodic leg movements during sleep in narcoleptic patients. Sleep (2011) 0.75
The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell (1999) 7.99
Hypocretin (orexin) deficiency in human narcolepsy. Lancet (2000) 7.92
A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med (2000) 7.05
Kleine-Levin syndrome: a systematic review of 186 cases in the literature. Brain (2005) 3.37
Familial patterns of narcolepsy. Lancet (1989) 3.07
Dopaminergic role in stimulant-induced wakefulness. J Neurosci (2001) 2.91
Pregnancy and the risk of stroke. N Engl J Med (1996) 2.68
Low cerebrospinal fluid hypocretin (Orexin) and altered energy homeostasis in human narcolepsy. Ann Neurol (2001) 2.47
Concomitant loss of dynorphin, NARP, and orexin in narcolepsy. Neurology (2005) 2.33
A CLOCK polymorphism associated with human diurnal preference. Sleep (1998) 2.24
Fluctuation of extracellular hypocretin-1 (orexin A) levels in the rat in relation to the light-dark cycle and sleep-wake activities. Eur J Neurosci (2001) 2.15
DQ (rather than DR) gene marks susceptibility to narcolepsy. Lancet (1992) 2.08
Association between apolipoprotein E epsilon4 and sleep-disordered breathing in adults. JAMA (2001) 2.05
Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome. Neurology (2003) 2.04
Mutation rate varies among alleles at a microsatellite locus: phylogenetic evidence. Proc Natl Acad Sci U S A (1996) 1.96
Iron and the restless legs syndrome. Sleep (1998) 1.87
Hypocretin-1 (orexin A) deficiency in acute traumatic brain injury. Neurology (2005) 1.76
Validation of a cataplexy questionnaire in 983 sleep-disorders patients. Sleep (1999) 1.76
MRI measurement of brain iron in patients with restless legs syndrome. Neurology (2001) 1.75
Cerebral infarction in young adults: the Baltimore-Washington Cooperative Young Stroke Study. Neurology (1998) 1.75
Increased carotid artery intimal-medial thickness in asymptomatic older subjects with exercise-induced myocardial ischemia. Circulation (1998) 1.65
Modafinil binds to the dopamine uptake carrier site with low affinity. Sleep (1994) 1.62
Identification and functional analysis of mutations in the hypocretin (orexin) genes of narcoleptic canines. Genome Res (2001) 1.59
Narcolepsy: clinical features, new pathophysiologic insights, and future perspectives. J Clin Neurophysiol (2001) 1.56
Restless legs syndrome: a review of clinical and pathophysiologic features. J Clin Neurophysiol (2001) 1.53
Pharmacological aspects of human and canine narcolepsy. Prog Neurobiol (1997) 1.53
CSF hypocretin levels in Guillain-Barré syndrome and other inflammatory neuropathies. Neurology (2003) 1.50
Medication use in patients with restless legs syndrome compared with a control population. Eur J Neurol (2007) 1.46
Subclinical sensory neuropathy in late-onset restless legs syndrome. Neurology (2000) 1.45
Locus coeruleus neurons: cessation of activity during cataplexy. Neuroscience (1999) 1.38
Narcolepsy and low CSF orexin (hypocretin) concentration after a diencephalic stroke. Neurology (2001) 1.36
CSF hypocretin/orexin levels in narcolepsy and other neurological conditions. Neurology (2001) 1.35
Construction and characterization of an eightfold redundant dog genomic bacterial artificial chromosome library. Genomics (1999) 1.30
APOE epsilon4 is associated with obstructive sleep apnea/hypopnea: the Sleep Heart Health Study. Neurology (2004) 1.28
Decreased transferrin receptor expression by neuromelanin cells in restless legs syndrome. Neurology (2004) 1.28
Neuronal activity in narcolepsy: identification of cataplexy-related cells in the medial medulla. Science (1991) 1.25
Hypocretin-1 CSF levels in anti-Ma2 associated encephalitis. Neurology (2004) 1.24
Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep (1996) 1.23
Changes in CSF hypocretin-1 (orexin A) levels in rats across 24 hours and in response to food deprivation. Neuroreport (2001) 1.12
Evaluation of the do not resuscitate orders at a community hospital. Arch Intern Med (1989) 1.12
Hypocretin deficiency in Prader-Willi syndrome. Eur J Neurol (2005) 1.10
HLA-DQB1*0602 homozygosity increases relative risk for narcolepsy but not disease severity in two ethnic groups. US Modafinil in Narcolepsy Multicenter Study Group. Tissue Antigens (1998) 1.10
Effect of aquatic weeds on methane emission from submerged paddy soil. Am J Bot (2001) 1.09
The development of hypocretin (orexin) deficiency in hypocretin/ataxin-3 transgenic rats. Neuroscience (2007) 1.09
Hypocretin/orexin, sleep and narcolepsy. Bioessays (2001) 1.09
A hypersomnolent girl with decreased CSF hypocretin level after removal of a hypothalamic tumor. Neurology (2001) 1.09
Normal hypocretin-1 levels in Parkinson's disease patients with excessive daytime sleepiness. Neurology (2002) 1.08
DQ microsatellite association studies in three ethnic groups. Tissue Antigens (1997) 1.06
Decreased brain histamine content in hypocretin/orexin receptor-2 mutated narcoleptic dogs. Neurosci Lett (2001) 1.04
The hypocretin neurotransmission system in myotonic dystrophy type 1. Neurology (2008) 1.03
Effects of thyrotropin-releasing hormone and its analogs on daytime sleepiness and cataplexy in canine narcolepsy. J Neurosci (1997) 1.03
Hypocretin levels in sporadic and familial cases of canine narcolepsy. Neurobiol Dis (2001) 1.02
Histamine H3 receptor antagonists: from target identification to drug leads. Biochem Pharmacol (2006) 1.01
Illicit drug-associated ischemic stroke in the Baltimore-Washington Young Stroke Study. Neurology (1998) 1.01
HLA-DQ association and allele competition in Chinese narcolepsy. Tissue Antigens (2012) 1.00
Narcolepsy-cataplexy associated with precocious puberty. Neurology (2006) 0.99
Gene localization and syntenic mapping by FISH in the dog. Cytogenet Cell Genet (1996) 0.99
Is narcolepsy a REM sleep disorder? Analysis of sleep abnormalities in narcoleptic Dobermans. Neurosci Res (2000) 0.99
Effects of sleep on the cardiovascular and thermoregulatory systems: a possible role for hypocretins. J Appl Physiol (1985) (2010) 0.99
HLA DR15 (DR2) and DQB1*0602 typing studies in 188 narcoleptic patients with cataplexy. Neurology (1997) 0.97
Homocyst(e)ine and risk of cerebral infarction in a biracial population : the stroke prevention in young women study. Stroke (1999) 0.95
Chronic oral administration of CG-3703, a thyrotropin releasing hormone analog, increases wake and decreases cataplexy in canine narcolepsy. Neuropsychopharmacology (2000) 0.95
Neuronal degeneration in canine narcolepsy. J Neurosci (1999) 0.95
Carotid arterial stiffness as a surrogate for aortic stiffness: relationship between carotid artery pressure-strain elastic modulus and aortic pulse wave velocity. Ultrasound Med Biol (1999) 0.94
Measurement of hypocretin/orexin content in the mouse brain using an enzyme immunoassay: the effect of circadian time, age and genetic background. Peptides (2002) 0.94
Hypocretin deficiency in familial symptomatic narcolepsy. Ann Neurol (2001) 0.94
HLA class II haplotype and sequence analysis support a role for DQ in narcolepsy. Immunogenetics (1997) 0.93
Family history study of the restless legs syndrome. Sleep Med (2002) 0.92
Implication of dopaminergic mechanisms in the wake-promoting effects of amphetamine: a study of D- and L-derivatives in canine narcolepsy. Neuroscience (2000) 0.92
Narcolepsy and the HLA region. J Neuroimmunol (2001) 0.92
Muscle atonia is triggered by cholinergic stimulation of the basal forebrain: implication for the pathophysiology of canine narcolepsy. J Neurosci (1995) 0.91
Influence of age and postmenopausal estrogen replacement therapy on carotid arterial stiffness in women. Cardiovasc Res (1999) 0.90
Loss of polyubiquitin gene Ubb leads to metabolic and sleep abnormalities in mice. Neuropathol Appl Neurobiol (2009) 0.90
CSF hypocretin-1 (orexin-A) levels in childhood narcolepsy and neurologic disorders. Neurology (2004) 0.90